SI1682180T1 - Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo - Google Patents

Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo

Info

Publication number: SI1682180T1
Authority: SI; Slovenia
Prior art keywords: methods; antagonist anti; dosing regimen; antibody; treating
Prior art date: 2003-11-04

Application number

SI200431280T

Other languages

English (en)

Slovenian (sl)

Inventor

Li Long

Mohammad Luqman

Asha Yabannavar

Isabel Zaror

Bao-Lu Chen

Xiaofeng Lu

Sang Hoon Lee

Deborah Hurst

Original Assignee

Novartis Vaccines & Diagnostic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-04

Filing date

2004-11-04

Publication date

2010-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34577667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1682180(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-04 Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic

2010-03-31 Publication of SI1682180T1 publication Critical patent/SI1682180T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)

SI200431280T 2003-11-04 2004-11-04 Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo SI1682180T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US51733703P	2003-11-04	2003-11-04
US52557903P	2003-11-26	2003-11-26
US56571004P	2004-04-27	2004-04-27
PCT/US2004/037152 WO2005044854A2 (fr)	2003-11-04	2004-11-04	Anticorps monoclonaux anti-cd40 antagonistes et procedes d'utilisation associes
EP04810510A EP1682180B1 (fr)	2003-11-04	2004-11-04	Anticorps monoclonaux anti-cd40 antagonistes et procedes d'utilisation associes

Publications (1)

Publication Number	Publication Date
SI1682180T1 true SI1682180T1 (sl)	2010-03-31

Family

ID=34577667

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200431514T SI1682178T1 (sl)	2003-11-04	2004-11-04	Postopki za terapijo raka ob eksprimiranju CD antigena
SI200431525T SI1694360T1 (sl)	2003-11-04	2004-11-04	Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
SI200431280T SI1682180T1 (sl)	2003-11-04	2004-11-04	Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SI200431514T SI1682178T1 (sl)	2003-11-04	2004-11-04	Postopki za terapijo raka ob eksprimiranju CD antigena
SI200431525T SI1694360T1 (sl)	2003-11-04	2004-11-04	Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa

Country Status (22)

Country	Link
EP (6)	EP1682178B8 (fr)
JP (6)	JP5019881B2 (fr)
KR (2)	KR101403910B1 (fr)
CN (2)	CN1905897B (fr)
AT (3)	ATE447412T1 (fr)
AU (3)	AU2004287482B2 (fr)
CA (3)	CA2544853C (fr)
CY (3)	CY1110231T1 (fr)
DE (3)	DE602004028505D1 (fr)
DK (4)	DK2149585T3 (fr)
EC (2)	ECSP066607A (fr)
ES (3)	ES2435410T3 (fr)
HR (2)	HRP20100066T1 (fr)
IL (1)	IL175225A (fr)
MA (1)	MA28331A1 (fr)
PL (4)	PL2149585T3 (fr)
PT (4)	PT2149585E (fr)
RS (2)	RS53073B (fr)
SG (1)	SG148143A1 (fr)
SI (3)	SI1682178T1 (fr)
WO (3)	WO2005044294A2 (fr)
ZA (1)	ZA200604419B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2236172A1 (fr) *	2003-11-04	2010-10-06	Novartis Vaccines and Diagnostics, Inc.	Thérapie combinée avec des anticorps anti-CD20 et anti-CD40 pour le traitment de cancers des cellules B
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
DK2149585T3 (da) *	2003-11-04	2013-10-21	Novartis Vaccines & Diagnostic	Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer
US20050281815A1 (en) *	2004-02-26	2005-12-22	Dani Eshel	CD40 splice variants and their uses
WO2006125143A2 (fr) *	2005-05-18	2006-11-23	Novartis Ag	Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
DK1889065T3 (da) *	2005-05-18	2013-09-02	Xoma Technology Ltd	Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
CN101217979A (zh)	2005-06-14	2008-07-09	安姆根有限公司	自缓冲蛋白制剂
US8926979B2 (en)	2005-11-01	2015-01-06	Novartis Ag	Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
US20090202531A1 (en) *	2005-11-01	2009-08-13	Novartis Ag	Uses of anti-cd40 antibodies
KR101906161B1 (ko)	2005-11-30	2018-10-11	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
WO2007067032A1 (fr)	2005-12-09	2007-06-14	Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam	Moyen et methodes permettant d'influencer la stabilite de cellules
CA3015416C (fr)	2005-12-09	2022-10-11	Academisch Medisch Centrum Bij De Universiteit Van Amsterdam	Moyen et methodes permettant d'influencer la stabilite de cellules produisant des anticorps
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MEP39508A (en) *	2006-04-21	2011-02-10	Novartis Ag	Antagonist anti-cd40 antibody pharmaceutical compositions
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2790018C (fr) *	2006-12-21	2015-02-03	Amgen Inc.	Formulations
EP2124952A2 (fr)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Méthode de traitement d'amyloïdoses
AU2008269086B2 (en)	2007-06-25	2014-06-12	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
MX2010005080A (es) *	2007-11-07	2010-07-28	Genentech Inc	Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
EP2211902A1 (fr) *	2007-11-09	2010-08-04	Novartis AG	Utilisation d'anticorps anti-cd40
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JP5836929B2 (ja)	2009-04-18	2015-12-24	ジェネンテック，インコーポレイテッド	抗ｃｄ４０抗体を用いる治療に対するｂ細胞性リンパ腫の応答性を評価するための方法
ES2666584T3 (es)	2009-07-15	2018-05-07	Aimm Therapeutics B.V.	Medios y métodos para producir anticuerpos de alta afinidad
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
US9062101B2 (en)	2010-08-14	2015-06-23	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
PL2635601T3 (pl)	2010-11-04	2017-02-28	Boehringer Ingelheim International Gmbh	Przeciwciała anty-il-23
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2016201742B2 (en) *	2010-11-15	2017-11-02	Novartis Ag	Silent Fc variants of anti-CD40 antibodies
WO2012075111A1 (fr)	2010-11-30	2012-06-07	Novartis Ag	Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
RU2585153C2 (ru)	2010-12-02	2016-05-27	Аимм Терапьютикс Б.В.	Средства и способы получения высокоаффинных антител
US9125893B2 (en)	2011-02-17	2015-09-08	Kyowa Hakko Kirin Co., Ltd.	Highly concentrated anti-CD40 antibody pharmaceutical preparation
US9713636B2 (en) *	2011-02-28	2017-07-25	Napajen Pharma, Inc.	Nucleic acid/polysaccharide complex
PL3556774T3 (pl)	2011-03-11	2024-07-01	Beth Israel Deaconess Medical Center Inc.	Przeciwciała anty-cd40 i ich zastosowania
AU2012245309C1 (en)	2011-04-21	2016-07-21	Bristol-Myers Squibb Company	Antibody polypeptides that antagonize CD40
HK1198689A1 (en)	2011-10-25	2015-05-29	Prothena Biosciences Limited	Antibody formulations and methods
WO2013072523A1 (fr)	2011-11-17	2013-05-23	Gundram Jung	Anticorps bispécifiques pour l'utilisation médicale
PL3326649T3 (pl) *	2012-05-03	2022-04-25	Boehringer Ingelheim International Gmbh	Przeciwciała anty-il-23p19
US20140004131A1 (en)	2012-05-04	2014-01-02	Novartis Ag	Antibody formulation
US9676861B2 (en) *	2012-10-30	2017-06-13	Apexigen, Inc.	Anti-CD40 antibodies and methods of use
JP6475631B2 (ja)	2012-11-19	2019-02-27	バリオファルム・アクチェンゲゼルシャフト	Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体
AU2014278833A1 (en) *	2013-06-13	2016-01-07	Fast Forward Pharmaceuticals B.V.	CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
DK3099709T3 (da)	2014-01-31	2020-02-03	Aimm Therapeutics Bv	Midler og fremgangsmåder til fremstilling af stabile antistoffer
US10435475B2 (en)	2014-03-07	2019-10-08	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize CD40 to treat IBD
US10519237B2 (en)	2014-03-12	2019-12-31	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en)	2014-03-12	2020-04-14	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CA2942245C (fr)	2014-03-12	2021-11-02	Yeda Research And Development Co. Ltd.	Reduction des niveaux ou de l'activite systemiques des lymphocytes t regulateurs en vue du traitement de maladies et de lesions touchant le snc
CN108025068A (zh) *	2014-03-12	2018-05-11	耶达研究与开发有限公司	降低系统性调节性t细胞水平或活性来治疗cns的疾病和损伤
KR20160124912A (ko) *	2014-03-19	2016-10-28	브리스톨-마이어스 스큅 컴퍼니	Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법
EP3708679A1 (fr)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarqueurs utiles dans le traitement de maladies liées à l'il-23a
WO2016029043A1 (fr)	2014-08-21	2016-02-25	The General Hospital Corporation	Mutéines de ligands de la superfamille du facteur de nécrose tumorale (tnfsf) et de ligands de type tnf et leurs procédés de préparation et d'utilisation
EA039598B9 (ru)	2014-09-03	2022-03-10	Бёрингер Ингельхайм Интернациональ Гмбх	Соединение, нацеленное на ил-23а и фно-альфа, и его применение
WO2016094679A1 (fr)	2014-12-10	2016-06-16	Regents Of The University Of Minnesota	Cellules, tissus et organes génétiquement modifiés pour le traitement d'une maladie
KR20240158362A (ko)	2015-02-04	2024-11-04	베링거 인겔하임 인터내셔날 게엠베하	염증성 질환의 치료 방법
DK3303395T3 (da)	2015-05-29	2020-01-27	Abbvie Inc	Anti-cd40-antistoffer og anvendelser deraf
SG10202101105XA (en)	2015-08-13	2021-03-30	Amgen Inc	Charged depth filtration of antigen-binding proteins
WO2017040932A1 (fr)	2015-09-04	2017-03-09	Primatope Therapeutics Inc.	Anticorps humanisés anti-cd40 et leurs utilisations
WO2017059196A2 (fr) *	2015-09-30	2017-04-06	Janssen Biotech, Inc.	Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
WO2017184619A2 (fr)	2016-04-18	2017-10-26	Celldex Therapeutics, Inc.	Anticorps agonistes se liant au cd40 humain et leurs utilisations
IL263834B2 (en)	2016-06-20	2024-01-01	Kymab Ltd	Anti-pd-l1 antibodies
KR20250097987A (ko)	2016-07-14	2025-06-30	젠맵 에이/에스	Cd40 및 cd137에 대한 다중특이적 항체
AU2018278051A1 (en) *	2017-06-01	2020-01-30	Jiangsu Hengrui Medicine Co., Ltd.	Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
CN111344304B (zh) *	2017-06-01	2023-09-01	Pb免疫治疗公司	新型抗cd40抗体及其用途
RS65380B1 (sr)	2017-08-24	2024-04-30	Novo Nordisk As	Glp-1 kompozicije i njihova upotreba
CN111868084B (zh) *	2018-01-29	2024-03-22	加利福尼亚大学董事会	治疗tlr2介导的疾病和病症的疗法和方法
CA3090322A1 (fr)	2018-02-12	2019-08-15	Diabetes-Free, Inc.	Anticorps monoclonaux anti-cd40 humain antagonistes ameliores
US20210251994A1 (en)	2018-06-15	2021-08-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
WO2020102454A1 (fr)	2018-11-13	2020-05-22	Regents Of The University Of Minnesota	Peptides ciblant le cd40 et leurs utilisations
AR117091A1 (es) *	2018-11-19	2021-07-07	Bristol Myers Squibb Co	Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP3962493A2 (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V, Inc.	Métodes de modulation de l'activité immunitaire
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115135304A (zh)	2020-02-18	2022-09-30	诺和诺德股份有限公司	Glp-1组合物及其用途
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CN111763259B (zh) *	2020-09-03	2020-12-15	北京百奥赛图基因生物技术有限公司	抗cd40抗体及其用途
HUE071594T2 (hu)	2021-01-28	2025-09-28	Regeneron Pharma	Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
US20240343817A1 (en) *	2021-07-14	2024-10-17	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Antibody that specifically recognizes cd40 and application thereof
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
CN117229396A (zh) *	2022-06-06	2023-12-15	普米斯生物技术(珠海)有限公司	抗cd40抗体及其用途
WO2024151687A1 (fr)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Commutateurs génétiques et leur utilisation dans le traitement du cancer
WO2025184567A1 (fr)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2025184603A2 (fr)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR901228A (fr)	1943-01-16	1945-07-20	Deutsche Edelstahlwerke Ag	Système d'aimant à entrefer annulaire
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3766162A (en)	1971-08-24	1973-10-16	Hoffmann La Roche	Barbituric acid antigens and antibodies specific therefor
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4233402A (en)	1978-04-05	1980-11-11	Syva Company	Reagents and method employing channeling
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0091539B2 (fr)	1982-03-31	1996-11-27	Ajinomoto Co., Inc.	Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules
CA1341562C (fr)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene codant pour un polypeptide ayant une activite interleukine 2, adn recombinant portant ledit gene, lignees cellulaires possedant ledit adn recombinant et procede pour la preparation d'interleukine 2 en utilisant lesdites cellules
BE893016R (fr)	1982-04-29	1982-08-16	Amatucci Aldo	Turbine a vent
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
FI82266C (fi)	1982-10-19	1991-02-11	Cetus Corp	Foerfarande foer framstaellning av il-2 -mutein.
US5700913A (en)	1982-12-15	1997-12-23	Ajinomoto Co., Inc.	Unglycosylated human interleukin-2 polypeptides
JPS60500673A (ja)	1983-03-08	1985-05-09	コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン	抗原活性を有するアミノ酸配列
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1985000817A1 (fr)	1983-08-10	1985-02-28	Amgen	Expression microbienne de l'interleukine ii
US4656132A (en)	1984-03-28	1987-04-07	Cetus Corporation	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4604377A (en)	1984-03-28	1986-08-05	Cetus Corporation	Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en)	1984-03-28	1985-07-23	Cetus Corporation	Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en)	1984-03-28	1986-02-11	Cetus Corporation	Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4572798A (en)	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
CA1340265C (fr)	1985-01-18	1998-12-15	Kirston E. Koths	Muteines resistant a l'oxydation
US4752585A (en)	1985-12-17	1988-06-21	Cetus Corporation	Oxidation-resistant muteins
US5981216A (en)	1985-04-01	1999-11-09	Alusuisse Holdings A.G.	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en)	1985-06-26	1988-05-31	Cetus Corporation	Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4816440A (en)	1985-09-26	1989-03-28	Cetus Corporation	Stable formulation of biologically active proteins for parenteral injection
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4745180A (en)	1986-06-27	1988-05-17	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using heparin fragments
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4931544A (en)	1986-09-04	1990-06-05	Cetus Corporation	Succinylated interleukin-2 for pharmaceutical compositions
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
CA1292686C (fr)	1986-10-27	1991-12-03	Ze'ev Shaked	Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
CA1294215C (fr)	1986-10-27	1992-01-14	Ze'ev Shaked	Compositions pharmaceutiques d'interferon beta recombinant et methodes de formulation
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US4931543A (en)	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5879936A (en)	1988-04-18	1999-03-09	Aluguisse Holding A.G.	Recombinant DNA methods, vectors and host cells
US5078997A (en)	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DE69019727T2 (de)	1989-09-21	1995-10-19	Idemitsu Kosan Co	Arylstyrolpolymer und -copolymer und verfahren zu ihrer herstellung.
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
SG48759A1 (en)	1990-01-12	2002-07-23	Abgenix Inc	Generation of xenogenic antibodies
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5891693A (en)	1990-01-25	1999-04-06	Alusuisse Holdings A.G.	Recombinant DNA methods vectors and host cells
IE66205B1 (en)	1990-06-14	1995-12-13	Paul A Bartlett	Polypeptide analogs
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
US5756096A (en)	1991-07-25	1998-05-26	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5962406A (en)	1991-10-25	1999-10-05	Immunex Corporation	Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
WO1994012520A1 (fr)	1992-11-20	1994-06-09	Enzon, Inc.	Segment de liaison pour polypeptides fusionnes lies
CA2115811A1 (fr)	1993-02-17	1994-08-18	Claus Krebber	Methode de selection in vivo de proteines fixatrices de ligands
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
ES2222463T3 (es)	1993-12-23	2005-02-01	Immunex Corporation	Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
AU683158B2 (en)	1994-03-03	1997-10-30	Alexion Pharmaceuticals, Inc.	Terminal complement inhibitor fusion genes and proteins
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US5830698A (en)	1997-03-14	1998-11-03	Idec Pharmaceuticals Corporation	Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
GB2339430A (en)	1997-05-21	2000-01-26	Biovation Ltd	Method for the production of non-immunogenic proteins
CA2292730C (fr)	1997-06-13	2008-09-16	Genentech, Inc.	Formulation stabilisee renfermant un anticorps
ATE272408T1 (de)	1997-06-20	2004-08-15	Biogen Idec Inc	Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
US6051228A (en) *	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
DZ2788A1 (fr)	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
US6168785B1 (en)	1998-07-16	2001-01-02	Institut Pasteur	Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
CA2342967A1 (fr)	1998-12-08	2000-06-15	Biovation Limited	Modification de l'immunogenicite de proteines
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
US6566500B1 (en)	1999-03-30	2003-05-20	Board Of Regents, The University Of Texas System	Compositions and methods for modifying toxic effects of proteinaceous compounds
AR023482A1 (es)	1999-04-16	2002-09-04	Hoffmann La Roche	Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
WO2001024814A1 (fr)	1999-10-04	2001-04-12	Chiron Corporation	Compositions pharmaceutiques liquides stabilisees contenant un polypeptide
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
AU1590201A (en) *	1999-11-09	2001-06-06	Chiron Corporation	Compositions and methods for treating autoimmune diseases and transplant rejections
ES2529300T3 (es)	2000-04-12	2015-02-18	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (fr) *	2000-04-28	2001-11-08	La Jolla Institute For Allergy And Immunology	Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
JP4271440B2 (ja)	2000-10-02	2009-06-03	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	ヒト抗ｃｄ４０抗体
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
CA2466931A1 (fr) *	2001-11-26	2003-06-05	Chiron Corporation	Traitement aux anticorps monoclonaux anti-cd40 antagonistes utilise pour traiter la sclerose en plaques
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
PT1682177E (pt) *	2003-11-04	2010-11-29	Xoma Technology Lt	Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
DK2149585T3 (da) *	2003-11-04	2013-10-21	Novartis Vaccines & Diagnostic	Anvendelse af antagonistiske anti-CD40-monoklonale antistoffer
EP1684805B8 (fr) *	2003-11-04	2010-08-25	Novartis Vaccines and Diagnostics, Inc.	Utilisation d'anticorps monoclonaux antagonistes anti-cd40 pour le traitement de myelome multiple
EP2301575A1 (fr) *	2003-11-04	2011-03-30	Novartis Vaccines and Diagnostics, Inc.	Procédé de thérapie pour tumeurs solides exprimant l'antigène de la surface de cellule CD40
EP2236172A1 (fr) *	2003-11-04	2010-10-06	Novartis Vaccines and Diagnostics, Inc.	Thérapie combinée avec des anticorps anti-CD20 et anti-CD40 pour le traitment de cancers des cellules B
JP6039343B2 (ja)	2012-10-04	2016-12-07	キヤノン株式会社	電子機器、電子機器の制御方法、プログラム、記憶媒体

2004
- 2004-11-04 DK DK09075395.5T patent/DK2149585T3/da active
- 2004-11-04 ES ES09075395T patent/ES2435410T3/es not_active Expired - Lifetime
- 2004-11-04 PL PL09075395T patent/PL2149585T3/pl unknown
- 2004-11-04 KR KR1020067010885A patent/KR101403910B1/ko not_active Expired - Fee Related
- 2004-11-04 JP JP2006538540A patent/JP5019881B2/ja not_active Expired - Lifetime
- 2004-11-04 HR HR20100066T patent/HRP20100066T1/hr unknown
- 2004-11-04 SG SG200808017-8A patent/SG148143A1/en unknown
- 2004-11-04 DK DK04810510T patent/DK1682180T3/da active
- 2004-11-04 CN CN2004800390435A patent/CN1905897B/zh not_active Expired - Lifetime
- 2004-11-04 RS RS20130482A patent/RS53073B/sr unknown
- 2004-11-04 ES ES04810510T patent/ES2333971T3/es not_active Expired - Lifetime
- 2004-11-04 EP EP04810421A patent/EP1682178B8/fr not_active Expired - Lifetime
- 2004-11-04 PT PT90753955T patent/PT2149585E/pt unknown
- 2004-11-04 CA CA2544853A patent/CA2544853C/fr not_active Expired - Fee Related
- 2004-11-04 PL PL04810420T patent/PL1694360T3/pl unknown
- 2004-11-04 CA CA2544949A patent/CA2544949C/fr not_active Expired - Fee Related
- 2004-11-04 DE DE602004028505T patent/DE602004028505D1/de not_active Expired - Lifetime
- 2004-11-04 AU AU2004287482A patent/AU2004287482B2/en not_active Ceased
- 2004-11-04 WO PCT/US2004/036958 patent/WO2005044294A2/fr not_active Ceased
- 2004-11-04 SI SI200431514T patent/SI1682178T1/sl unknown
- 2004-11-04 AT AT04810510T patent/ATE447412T1/de active
- 2004-11-04 EP EP10007970A patent/EP2248830A1/fr not_active Withdrawn
- 2004-11-04 EP EP04810420A patent/EP1694360B1/fr not_active Expired - Lifetime
- 2004-11-04 DK DK04810420.2T patent/DK1694360T3/da active
- 2004-11-04 PT PT04810420T patent/PT1694360E/pt unknown
- 2004-11-04 RS RSP-2010/0041A patent/RS51230B/sr unknown
- 2004-11-04 DE DE602004023961T patent/DE602004023961D1/de not_active Expired - Lifetime
- 2004-11-04 SI SI200431525T patent/SI1694360T1/sl unknown
- 2004-11-04 KR KR1020067010894A patent/KR101125127B1/ko not_active Expired - Fee Related
- 2004-11-04 WO PCT/US2004/037152 patent/WO2005044854A2/fr not_active Ceased
- 2004-11-04 PT PT04810421T patent/PT1682178E/pt unknown
- 2004-11-04 CA CA002544948A patent/CA2544948A1/fr not_active Abandoned
- 2004-11-04 AU AU2004287879A patent/AU2004287879C1/en not_active Ceased
- 2004-11-04 DK DK04810421.0T patent/DK1682178T3/da active
- 2004-11-04 ZA ZA200604419A patent/ZA200604419B/xx unknown
- 2004-11-04 EP EP09075395.5A patent/EP2149585B1/fr not_active Expired - Lifetime
- 2004-11-04 JP JP2006538514A patent/JP4765039B2/ja not_active Expired - Fee Related
- 2004-11-04 WO PCT/US2004/036957 patent/WO2005044306A2/fr not_active Ceased
- 2004-11-04 CN CN200480037489.4A patent/CN1938045B/zh not_active Expired - Lifetime
- 2004-11-04 PT PT04810510T patent/PT1682180E/pt unknown
- 2004-11-04 DE DE602004028037T patent/DE602004028037D1/de not_active Expired - Lifetime
- 2004-11-04 JP JP2006538513A patent/JP4746552B2/ja not_active Expired - Lifetime
- 2004-11-04 ES ES04810421T patent/ES2346977T3/es not_active Expired - Lifetime
- 2004-11-04 AT AT04810420T patent/ATE476448T1/de active
- 2004-11-04 SI SI200431280T patent/SI1682180T1/sl unknown
- 2004-11-04 EP EP04810510A patent/EP1682180B1/fr not_active Expired - Lifetime
- 2004-11-04 PL PL04810510T patent/PL1682180T3/pl unknown
- 2004-11-04 PL PL04810421T patent/PL1682178T3/pl unknown
- 2004-11-04 EP EP10006780A patent/EP2255828A1/fr not_active Withdrawn
- 2004-11-04 AT AT04810421T patent/ATE473016T1/de active
2006
- 2006-04-26 IL IL175225A patent/IL175225A/en not_active IP Right Cessation
- 2006-06-05 MA MA29078A patent/MA28331A1/fr unknown
- 2006-06-05 EC EC2006006607A patent/ECSP066607A/es unknown
2010
- 2010-01-15 CY CY20101100045T patent/CY1110231T1/el unknown
- 2010-09-28 CY CY20101100869T patent/CY1110803T1/el unknown
- 2010-10-18 CY CY20101100931T patent/CY1110839T1/el unknown
- 2010-12-13 JP JP2010277537A patent/JP2011072317A/ja not_active Withdrawn
2011
- 2011-02-18 JP JP2011033969A patent/JP2011126900A/ja not_active Withdrawn
- 2011-02-25 JP JP2011040922A patent/JP2011105769A/ja not_active Withdrawn
- 2011-04-05 AU AU2011201529A patent/AU2011201529B2/en not_active Ceased
2012
- 2012-03-05 EC ECSP12006607 patent/ECSP12006607A/es unknown
2013
- 2013-11-13 HR HRP20131085TT patent/HRP20131085T1/hr unknown

Also Published As

Publication number	Publication date
PL1682180T3 (pl)	2010-04-30
CN1938045A (zh)	2007-03-28
CA2544949A1 (fr)	2005-05-19
DE602004023961D1 (de)	2009-12-17
AU2011201529B2 (en)	2012-11-01
ATE473016T1 (de)	2010-07-15
JP2011072317A (ja)	2011-04-14
DE602004028037D1 (de)	2010-08-19
RS51230B (sr)	2010-12-31
EP1694360B1 (fr)	2010-08-04
JP2008502309A (ja)	2008-01-31
HRP20100066T1 (hr)	2010-03-31
WO2005044294A2 (fr)	2005-05-19
HK1094156A1 (en)	2007-03-23
CY1110231T1 (el)	2015-01-14
CA2544949C (fr)	2014-02-25
CA2544853A1 (fr)	2005-05-19
EP1682180B1 (fr)	2009-11-04
PT1682180E (pt)	2010-02-10
EP1682178A2 (fr)	2006-07-26
EP2248830A1 (fr)	2010-11-10
CN1905897A (zh)	2007-01-31
ATE476448T1 (de)	2010-08-15
DK2149585T3 (da)	2013-10-21
WO2005044854A2 (fr)	2005-05-19
JP5019881B2 (ja)	2012-09-05
EP2255828A1 (fr)	2010-12-01
PL1694360T3 (pl)	2011-04-29
EP1682178B8 (fr)	2010-09-01
CN1905897B (zh)	2012-09-05
ECSP066607A (es)	2006-10-25
ZA200604419B (en)	2008-06-25
PT1682178E (pt)	2010-10-21
AU2004287879A1 (en)	2005-05-19
IL175225A0 (en)	2006-09-05
PT2149585E (pt)	2013-11-27
KR20060111555A (ko)	2006-10-27
AU2004287482B2 (en)	2011-04-14
PL2149585T3 (pl)	2014-01-31
CN1938045B (zh)	2014-03-26
EP1682178B1 (fr)	2010-07-07
MA28331A1 (fr)	2006-12-01
SI1682178T1 (sl)	2010-11-30
KR101125127B1 (ko)	2012-03-16
DK1682180T3 (da)	2010-01-11
DE602004028505D1 (de)	2010-09-16
ES2333971T3 (es)	2010-03-03
AU2004287879C1 (en)	2011-05-26
CA2544853C (fr)	2014-05-20
JP2011105769A (ja)	2011-06-02
SI1694360T1 (sl)	2010-12-31
ECSP12006607A (es)	2012-04-30
WO2005044306A2 (fr)	2005-05-19
PL1682178T3 (pl)	2010-12-31
WO2005044854A3 (fr)	2005-08-11
WO2005044294A3 (fr)	2005-09-15
HK1095270A1 (en)	2007-05-04
HRP20131085T1 (hr)	2013-12-20
ATE447412T1 (de)	2009-11-15
KR101403910B1 (ko)	2014-06-09
AU2011201529A1 (en)	2011-04-28
DK1694360T3 (da)	2010-10-18
JP2007512243A (ja)	2007-05-17
ES2435410T3 (es)	2013-12-19
ES2346977T3 (es)	2010-10-22
IL175225A (en)	2011-12-29
JP4765039B2 (ja)	2011-09-07
JP2011126900A (ja)	2011-06-30
WO2005044306A3 (fr)	2005-09-15
CY1110803T1 (el)	2015-06-10
HK1139964A1 (en)	2010-09-30
CY1110839T1 (el)	2015-06-10
EP1682180A2 (fr)	2006-07-26
AU2004287482A1 (en)	2005-05-19
EP2149585A1 (fr)	2010-02-03
DK1682178T3 (da)	2010-10-04
PT1694360E (pt)	2010-12-13
KR20060132602A (ko)	2006-12-21
AU2004287879B2 (en)	2011-01-06
JP4746552B2 (ja)	2011-08-10
CA2544948A1 (fr)	2005-05-19
RS53073B (sr)	2014-04-30
JP2007510666A (ja)	2007-04-26
EP1694360A2 (fr)	2006-08-30
SG148143A1 (en)	2008-12-31
HK1095091A1 (en)	2007-04-27
EP2149585B1 (fr)	2013-08-14

Publication	Publication Date	Title
ZA200604419B (en)	2008-06-25	Antagonist anti-CD40 monoclonal antibodies and methods for their use
PL1684869T3 (pl)	2011-12-30	Sposoby leczenia nowotworów wywodzących się z limfocytów B
EP1717251A3 (fr)	2007-11-07	Anticorps humains anti-CD40 pour le traitement des tumeurs malignes des lymphocytes B
CY1110874T1 (el)	2015-06-10	Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
SI1684805T1 (sl)	2010-11-30	Uporaba antagonističnih anti CD monoklonskih protiteles za zdravljenje multiplega mieloma
WO2003061571A3 (fr)	2005-07-07	Therapie combinee avec il-2 et des anticorps anti-her2 pour les cancers caracterises par la surexpression de la proteine receptrice her2
CA2368676A1 (fr)	2000-10-05	Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs
RU2013127115A (ru)	2014-12-27	Комбинированная терапия при в-клеточных лимфомах
EP1935431A3 (fr)	2008-08-13	Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2